| NCT07045701 | FMXIN002 in Patients at Risk of Anaphylaxis | ENROLLING_BY_INVITATION | PHASE2, PHASE3 | 2025-06-12 | 2026-07-12 | 2026-06-12 |
| NCT06205134 | Comparative Bioavailability of Intranasal Epinephrine | COMPLETED | PHASE1, PHASE2 | 2023-08-22 | 2024-02-05 | 2024-02-02 |
| NCT05252468 | COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIXâ„¢ on Infection Rate by SARS-CoV-2 Virus (COVID-19). | COMPLETED | NA | 2021-05-19 | 2021-12-02 | 2021-11-02 |
| NCT04713709 | A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder | COMPLETED | PHASE1 | 2021-01-31 | 2021-10-10 | 2021-03-30 |
| NCT04696822 | Bioavailability of Nasal Epinephrine | COMPLETED | PHASE1 | 2020-11-01 | 2021-09-28 | 2021-09-28 |